Enosi Life Sciences: Dr. James N. Woody
Enosi Life Sciences, a San Diego drug research and development company, has appointed antibody therapeutics pioneer Dr. James N. Woody as Executive Chairman.
The former Commanding Officer and Director of the U.S. Naval Medical Research and Development Command has more than 25 years of leadership experience in the biotech, pharmaceutical and venture capital sectors. Dr. Woody led the Centocor team that developed Remicade, the first tumor necrosis factor (TNF) inhibitor biologic, working with Sir Ravinder Maini and Sir Marc Feldmann.
His experience will now be used to lead Enosi’s development of anti-TNF therapeutics for inflammation, autoimmune diseases and cancer.
Dr. Woody has also previously served as CEO of MaraBio Systems, Chairman of the Board of Viracta Therapeutics, General Partner of Latterell Venture Partners, Founding President and CEO of OncoMed Pharmaceuticals, President and General Manager of Roche Biosciences (formerly Syntex Pharmaceuticals), and Senior Vice President and Chief Scientific Officer of Centocor.
In his role with the U.S. Navy, Dr. Woody and his colleagues founded the National Marrow Donor Program, which provides matched bone marrow for recipients without matched donors.
He holds a Doctor of Medicine from the Loma Linda University School of Medicine, and a Doctor of Philosophy in Immunology from University College London.
Pic:getty/benny winslow
